Injectable Biopolymer-Based Hydrogels: A Next-Generation Platform for Minimally Invasive Therapeutics
Parvin N., Joo SW., Mandal TK.
Narrative Review, published in Gels (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Gels (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40558682
- PMCID
- PMC12192118
- DOI
- 10.3390/gels11060383
- Citations
- 14
Abstract (original English)
Injectable biopolymer-based hydrogels have emerged as a powerful class of biomaterials designed for minimally invasive therapeutic strategies in modern medicine. These smart hydrogels, derived from natural biopolymers, such as alginate, chitosan, gelatin, hyaluronic acid, and collagen, offer unique advantages, including biocompatibility, biodegradability, and the ability to mimic the extracellular matrix. This review provides a comprehensive overview of recent advancements in the design, crosslinking mechanisms, and biofunctionality of injectable hydrogels tailored for targeted drug delivery and tissue regeneration. Special attention is given to their role in in situ gelling systems, cancer therapy, musculoskeletal repair, and neural regeneration. Challenges related to mechanical strength, degradation control, and clinical translation are also discussed, along with future perspectives for scalable manufacturing and regulatory approval.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.